Deborah A. Robins

3.7k total citations · 5 hit papers
27 papers, 2.7k citations indexed

About

Deborah A. Robins is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Pharmacology. According to data from OpenAlex, Deborah A. Robins has authored 27 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Endocrinology, Diabetes and Metabolism, 15 papers in Molecular Biology and 6 papers in Pharmacology. Recurrent topics in Deborah A. Robins's work include Diabetes Treatment and Management (13 papers), Metabolism, Diabetes, and Cancer (9 papers) and Pharmacology and Obesity Treatment (6 papers). Deborah A. Robins is often cited by papers focused on Diabetes Treatment and Management (13 papers), Metabolism, Diabetes, and Cancer (9 papers) and Pharmacology and Obesity Treatment (6 papers). Deborah A. Robins collaborates with scholars based in United States, Singapore and Japan. Deborah A. Robins's co-authors include Axel Haupt, Charles Benson, Xuewei Cui, Zvonko Miličević, Juan P. Frías, Kevin L. Duffin, Michael A. Nauck, Shweta Urva, Joanna Van and Ross Bray and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Deborah A. Robins

25 papers receiving 2.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

2018 610 citations Juan P. Frías, Michael A. Nauck et al. The Lancet profile →
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis

2024 353 citations Rohit Loomba, Mark L. Hartman et al. New England Journal of Medicine profile →
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes

2020 271 citations Mark L. Hartman, Arun J. Sanyal et al. Diabetes Care profile →
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

2023 259 citations Sean Wharton, Thomas Blevins et al. New England Journal of Medicine profile →
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study

2023 97 citations Juan P. Frías, Stanley H. Hsia et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Deborah A. Robins United States	17	1.8k	974	650	629	622	27	2.7k
Florian M.M. Baeres Denmark	13	950 0.5×	470 0.5×	219 0.3×	215 0.3×	436 0.7×	31	1.9k
David R. Powell United States	27	1.8k 1.0×	1.0k 1.0×	131 0.2×	338 0.5×	856 1.4×	39	2.6k
Meena Asmar Denmark	22	1.2k 0.7×	595 0.6×	256 0.4×	297 0.5×	660 1.1×	32	1.7k
Iseki Takamoto Japan	20	429 0.2×	738 0.8×	88 0.1×	518 0.8×	490 0.8×	31	1.7k
Stefan Aczél Austria	21	523 0.3×	369 0.4×	125 0.2×	198 0.3×	349 0.6×	38	1.4k
Jee‐Young Han South Korea	29	570 0.3×	670 0.7×	207 0.3×	293 0.5×	341 0.5×	56	2.1k
Winfried Maerz Germany	22	438 0.2×	387 0.4×	158 0.2×	247 0.4×	519 0.8×	45	1.9k
Kohzo Takebayashi Japan	24	630 0.4×	522 0.5×	123 0.2×	402 0.6×	306 0.5×	78	2.0k
Penny Clark United Kingdom	16	1.4k 0.8×	717 0.7×	164 0.3×	344 0.5×	1.4k 2.3×	19	2.6k
Timo Sane Finland	26	1.4k 0.8×	352 0.4×	110 0.2×	170 0.3×	661 1.1×	47	2.2k

Countries citing papers authored by Deborah A. Robins

Since Specialization

Citations

This map shows the geographic impact of Deborah A. Robins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah A. Robins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah A. Robins more than expected).

Fields of papers citing papers by Deborah A. Robins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah A. Robins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah A. Robins. The network helps show where Deborah A. Robins may publish in the future.

Co-authorship network of co-authors of Deborah A. Robins

This figure shows the co-authorship network connecting the top 25 collaborators of Deborah A. Robins. A scholar is included among the top collaborators of Deborah A. Robins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah A. Robins. Deborah A. Robins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rosenstock, Julio, Deborah A. Robins, Kevin L. Duffin, et al.. (2025). Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes. Diabetes Obesity and Metabolism. 27(11). 6314–6322. 1 indexed citations

Loomba, Rohit, Mark L. Hartman, Eric Lawitz, et al.. (2024). Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis. New England Journal of Medicine. 391(4). 299–310. 353 indexed citations breakdown →

Robins, Deborah A., et al.. (2024). 229-OR: Orforglipron Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes. Diabetes. 73(Supplement_1).

Pratt, Edward, Xiaosu Ma, Rong Liu, et al.. (2023). Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants. Diabetes Obesity and Metabolism. 25(9). 2634–2641. 23 indexed citations

Pratt, Edward, Xiaosu Ma, Rong Liu, et al.. (2023). Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes. Diabetes Obesity and Metabolism. 25(9). 2642–2649. 34 indexed citations

Frías, Juan P., Stanley H. Hsia, Rong Liu, et al.. (2023). Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. The Lancet. 402(10400). 472–483. 97 indexed citations breakdown →

Bénichou, Olivier, Tamer Coşkun, Malgorzata D. Gonciarz, et al.. (2023). Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist. Cell Metabolism. 35(2). 274–286.e10. 52 indexed citations

Wharton, Sean, Thomas Blevins, Lisa Connery, et al.. (2023). Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. New England Journal of Medicine. 389(10). 877–888. 259 indexed citations breakdown →

Robins, Deborah A., et al.. (2022). 336-OR: A First-in-Human Single- and Multiple-Ascending Dose Study Evaluating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Nonpeptide GLP-1 Receptor Agonist in Healthy Subjects. Diabetes. 71(Supplement_1). 2 indexed citations

10.

Wilson, Jonathan M., Yanzhu Lin, Mengdie Luo, et al.. (2021). The dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A p ost hoc analysis. Diabetes Obesity and Metabolism. 24(1). 148–153. 89 indexed citations

11.

Frías, Juan P., Michael A. Nauck, Joanna Van, et al.. (2020). Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens. Diabetes Obesity and Metabolism. 22(6). 938–946. 171 indexed citations

12.

Wilson, Jonathan M., Amir Nikooienejad, Deborah A. Robins, et al.. (2020). The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes Obesity and Metabolism. 22(12). 2451–2459. 113 indexed citations

13.

Thomas, Melissa K., Amir Nikooienejad, Ross Bray, et al.. (2020). Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 106(2). 388–396. 220 indexed citations

14.

Hartman, Mark L., Arun J. Sanyal, Rohit Loomba, et al.. (2020). Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes. Diabetes Care. 43(6). 1352–1355. 271 indexed citations breakdown →

15.

Thomas, Melissa K., Amir Nikooienejad, Ross Bray, et al.. (2019). 980-P: Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes Patients. Diabetes. 68(Supplement_1). 5 indexed citations

16.

Frías, Juan P., Michael A. Nauck, Joanna Van, et al.. (2018). Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. The Lancet. 392(10160). 2180–2193. 610 indexed citations breakdown →

17.

Krishnan, Venkatesh, Nita Patel, Stephanie A. Sweetana, et al.. (2018). Development of a selective androgen receptor modulator for transdermal use in hypogonadal patients. Andrology. 6(3). 455–464. 14 indexed citations

18.

Recker, Robert R., Charles Benson, Toshio Matsumoto, et al.. (2014). A Randomized, Double-Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density. Journal of Bone and Mineral Research. 30(2). 216–224. 216 indexed citations

19.

Benson, Charles, Deborah A. Robins, Robert R. Recker, et al.. (2013). Effect of blosozumab on bone mineral density: results of a phase 2 study of postmenopausal women with low bone mineral density. Bone Abstracts. 6 indexed citations

20.

Eriksen, Erik Fink & Deborah A. Robins. (2004). Teriparatide: A bone formation treatment for osteoporosis. Drugs of today. 40(11). 935–935. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact